-
1
-
-
3242699423
-
Mechanisms of lysophosphatidic acid production
-
Aoki J. Mechanisms of lysophosphatidic acid production. Semin. Cell Dev. Biol. 2004, 15:477-489.
-
(2004)
Semin. Cell Dev. Biol.
, vol.15
, pp. 477-489
-
-
Aoki, J.1
-
2
-
-
67849122340
-
Regulation of blood and vascular cell function by bioactive lysophospholipids
-
Morris A.J., Panchatcharam M., Cheng H.Y., et al. Regulation of blood and vascular cell function by bioactive lysophospholipids. J. Thromb. Haemost. 2009, 7(Suppl. 1):38-43.
-
(2009)
J. Thromb. Haemost.
, vol.7
, Issue.SUPPL. 1
, pp. 38-43
-
-
Morris, A.J.1
Panchatcharam, M.2
Cheng, H.Y.3
-
3
-
-
49949110717
-
Roles of lysophosphatidic acid in cardiovascular physiology and disease
-
Smyth S.S., Cheng H.Y., Miriyala S., Panchatcharam M., Morris A.J. Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim. Biophys. Acta 2008, 1781:563-570.
-
(2008)
Biochim. Biophys. Acta
, vol.1781
, pp. 563-570
-
-
Smyth, S.S.1
Cheng, H.Y.2
Miriyala, S.3
Panchatcharam, M.4
Morris, A.J.5
-
4
-
-
0033536049
-
Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions
-
Siess W., Zangl K.J., Essler M., et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6931-6936.
-
(1999)
Proc. Natl. Acad. Sci. U. S. A.
, vol.96
, pp. 6931-6936
-
-
Siess, W.1
Zangl, K.J.2
Essler, M.3
-
5
-
-
0035800886
-
Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids
-
Hayashi K., Takahashi M., Nishida W., et al. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ. Res. 2001, 89:251-258.
-
(2001)
Circ. Res.
, vol.89
, pp. 251-258
-
-
Hayashi, K.1
Takahashi, M.2
Nishida, W.3
-
6
-
-
12144288490
-
Lysophosphatidic acid induces neointima formation through PPARgamma activation
-
Zhang C., Baker D.L., Yasuda S., et al. Lysophosphatidic acid induces neointima formation through PPARgamma activation. J. Exp. Med. 2004, 199:763-774.
-
(2004)
J. Exp. Med.
, vol.199
, pp. 763-774
-
-
Zhang, C.1
Baker, D.L.2
Yasuda, S.3
-
7
-
-
79955596968
-
Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium
-
Zhou Z., Subramanian P., Sevilmis G., et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 2011, 13:592-600.
-
(2011)
Cell Metab.
, vol.13
, pp. 592-600
-
-
Zhou, Z.1
Subramanian, P.2
Sevilmis, G.3
-
8
-
-
1542359873
-
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production
-
Umezu-Goto M., Kishi Y., Taira A., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 2002, 158:227-233.
-
(2002)
J. Cell Biol.
, vol.158
, pp. 227-233
-
-
Umezu-Goto, M.1
Kishi, Y.2
Taira, A.3
-
9
-
-
0037131366
-
Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase
-
Tokumura A., Majima E., Kariya Y., et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 2002, 277:39436-39442.
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 39436-39442
-
-
Tokumura, A.1
Majima, E.2
Kariya, Y.3
-
10
-
-
33745466418
-
Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development
-
van Meeteren L.A., Ruurs P., Stortelers C., et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 2006, 26:5015-5022.
-
(2006)
Mol. Cell Biol.
, vol.26
, pp. 5015-5022
-
-
van Meeteren, L.A.1
Ruurs, P.2
Stortelers, C.3
-
11
-
-
79551636074
-
Structural basis of substrate discrimination and integrin binding by autotaxin
-
Hausmann J., Kamtekar S., Christodoulou E., et al. Structural basis of substrate discrimination and integrin binding by autotaxin. Nat. Struct. Mol. Biol. 2011, 18:198-204.
-
(2011)
Nat. Struct. Mol. Biol.
, vol.18
, pp. 198-204
-
-
Hausmann, J.1
Kamtekar, S.2
Christodoulou, E.3
-
12
-
-
79551646019
-
Crystal structure of autotaxin and insight into GPCR activation by lipid mediators
-
Nishimasu H., Okudaira S., Hama K., et al. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat. Struct. Mol. Biol. 2011, 18:205-212.
-
(2011)
Nat. Struct. Mol. Biol.
, vol.18
, pp. 205-212
-
-
Nishimasu, H.1
Okudaira, S.2
Hama, K.3
-
13
-
-
0038043168
-
Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity
-
Ferry G., Tellier E., Try A., et al. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J. Biol. Chem. 2003, 278:18162-18169.
-
(2003)
J. Biol. Chem.
, vol.278
, pp. 18162-18169
-
-
Ferry, G.1
Tellier, E.2
Try, A.3
-
14
-
-
84866005911
-
Lysophosphatidic acid in atherosclerotic diseases
-
Schober A., Siess W. Lysophosphatidic acid in atherosclerotic diseases. Br. J. Pharmacol. 2012, 167:465-482.
-
(2012)
Br. J. Pharmacol.
, vol.167
, pp. 465-482
-
-
Schober, A.1
Siess, W.2
-
15
-
-
77949492248
-
Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance
-
Lin M.E., Herr D.R., Chun J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 2010, 91:130-138.
-
(2010)
Prostaglandins Other Lipid Mediat.
, vol.91
, pp. 130-138
-
-
Lin, M.E.1
Herr, D.R.2
Chun, J.3
-
16
-
-
79952842711
-
GPR92/LPA(5) lysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques
-
Khandoga A.L., Pandey D., Welsch U., Brandl R., Siess W. GPR92/LPA(5) lysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques. Cardiovasc. Res. 2011, 90:157-164.
-
(2011)
Cardiovasc. Res.
, vol.90
, pp. 157-164
-
-
Khandoga, A.L.1
Pandey, D.2
Welsch, U.3
Brandl, R.4
Siess, W.5
-
17
-
-
0141919734
-
Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo
-
Yoshida K., Nishida W., Hayashi K., et al. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 2003, 108:1746-1752.
-
(2003)
Circulation
, vol.108
, pp. 1746-1752
-
-
Yoshida, K.1
Nishida, W.2
Hayashi, K.3
-
18
-
-
0037137299
-
Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease
-
Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
-
(2002)
Circulation
, vol.106
, pp. 2747-2757
-
-
Kris-Etherton, P.M.1
Harris, W.S.2
Appel, L.J.3
-
19
-
-
45849092920
-
Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases
-
Li Z.G., Yu Z.C., Wang D.Z., et al. Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. Neurol. Res. 2008, 30:366-369.
-
(2008)
Neurol. Res.
, vol.30
, pp. 366-369
-
-
Li, Z.G.1
Yu, Z.C.2
Wang, D.Z.3
-
20
-
-
77951634698
-
The effects of EPA, DHA, and aspirin ingestion on plasma lysophospholipids and autotaxin
-
Block R.C., Duff R., Lawrence P., et al. The effects of EPA, DHA, and aspirin ingestion on plasma lysophospholipids and autotaxin. Prostaglandins Leukot. Essent. Fatty Acids 2010, 82:87-95.
-
(2010)
Prostaglandins Leukot. Essent. Fatty Acids
, vol.82
, pp. 87-95
-
-
Block, R.C.1
Duff, R.2
Lawrence, P.3
-
21
-
-
84879000451
-
Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus
-
Block R.C., Abdolahi A., Smith B., et al. Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus. Prostaglandins Leukot. Essent. Fatty Acids 2013, 89:9-18.
-
(2013)
Prostaglandins Leukot. Essent. Fatty Acids
, vol.89
, pp. 9-18
-
-
Block, R.C.1
Abdolahi, A.2
Smith, B.3
-
22
-
-
84859247836
-
Executive summary: standards of medical care in diabetes - 2012
-
American Diabetes Association
-
Executive summary: standards of medical care in diabetes - 2012. Diabetes Care 2012, 32:S4-S10. American Diabetes Association.
-
(2012)
Diabetes Care
, vol.32
-
-
-
23
-
-
34248352504
-
Aspirin dose for the prevention of cardiovascular disease: a systematic review
-
Campbell C.L., Smyth S., Montalescot G., Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. J. Am. Med. Assoc. 2007, 297:2018-2024.
-
(2007)
J. Am. Med. Assoc.
, vol.297
, pp. 2018-2024
-
-
Campbell, C.L.1
Smyth, S.2
Montalescot, G.3
Steinhubl, S.R.4
-
24
-
-
40749134619
-
Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway
-
Pamuklar Z., Lee J.S., Cheng H.Y., et al. Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler. Thromb. Vasc. Biol. 2008, 28:555-561.
-
(2008)
Arterioscler. Thromb. Vasc. Biol.
, vol.28
, pp. 555-561
-
-
Pamuklar, Z.1
Lee, J.S.2
Cheng, H.Y.3
-
25
-
-
84864365428
-
Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes
-
Barber M.N., Risis S., Yang C., et al. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS One 2012, 7:e41456.
-
(2012)
PLoS One
, vol.7
-
-
Barber, M.N.1
Risis, S.2
Yang, C.3
-
26
-
-
84971579967
-
-
Anonymous, Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration, BMJ
-
Anonymous, Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration, BMJ, 308, 1994, pp. 81-106.
-
(1994)
, vol.308
, pp. 81-106
-
-
-
27
-
-
0842277242
-
-
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition, Circulation
-
S.M. Grundy, H.B. Brewer, Jr., J.I. Cleeman, S.C. Smith, Jr., C. Lenfant, Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition, Circulation, 109, 2004, pp. 433-438.
-
(2004)
, vol.109
, pp. 433-438
-
-
Grundy, S.M.1
Brewer Jr., H.B.2
Cleeman, J.I.3
Smith Jr., S.C.4
Lenfant, C.5
-
28
-
-
0024406369
-
-
Steering Committee of the Physicians' Health Study Research Group, Final report on the aspirin component of the ongoing Physicians' Health Study, N. Engl. J. Med.
-
Steering Committee of the Physicians' Health Study Research Group, Final report on the aspirin component of the ongoing Physicians' Health Study, N. Engl. J. Med., 321, 1989, pp. 129-135.
-
(1989)
, vol.321
, pp. 129-135
-
-
-
29
-
-
34347340649
-
Evaluation of dose-related effects of aspirin on platelet function: results from the aspirin-induced platelet effect (ASPECT) study
-
Gurbel P.A., Bliden K.P., DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the aspirin-induced platelet effect (ASPECT) study. Circulation 2007, 115:3156-3164.
-
(2007)
Circulation
, vol.115
, pp. 3156-3164
-
-
Gurbel, P.A.1
Bliden, K.P.2
DiChiara, J.3
-
30
-
-
33646761285
-
Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients
-
Ohmori T., Yatomi Y., Nonaka T., et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J. Thromb. Haemost. 2006, 4:1271-1278.
-
(2006)
J. Thromb. Haemost.
, vol.4
, pp. 1271-1278
-
-
Ohmori, T.1
Yatomi, Y.2
Nonaka, T.3
-
31
-
-
0018152134
-
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?
-
Dyerberg J., Bang H.O., Stoffersen E., Moncada S., Vane J.R. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet 1978, 2:117-119.
-
(1978)
Lancet
, vol.2
, pp. 117-119
-
-
Dyerberg, J.1
Bang, H.O.2
Stoffersen, E.3
Moncada, S.4
Vane, J.R.5
-
32
-
-
0020693482
-
Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects
-
Terano T., Hirai A., Hamazaki T., et al. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983, 46:321-331.
-
(1983)
Atherosclerosis
, vol.46
, pp. 321-331
-
-
Terano, T.1
Hirai, A.2
Hamazaki, T.3
-
33
-
-
1042268057
-
Aspirin therapy in diabetes
-
Colwell J.A. Aspirin therapy in diabetes. Diabetes Care 2004, 27(Suppl. 1):S72-S73.
-
(2004)
Diabetes Care
, vol.27
, Issue.SUPPL. 1
-
-
Colwell, J.A.1
-
34
-
-
10944239058
-
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)
-
Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004, 110:e82-292.
-
(2004)
Circulation
, vol.110
-
-
Antman, E.M.1
Anbe, D.T.2
Armstrong, P.W.3
-
35
-
-
0022623355
-
Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma
-
Tokumura A., Harada K., Fukuzawa K., Tsukatani H. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim. Biophys. Acta 1986, 875:31-38.
-
(1986)
Biochim. Biophys. Acta
, vol.875
, pp. 31-38
-
-
Tokumura, A.1
Harada, K.2
Fukuzawa, K.3
Tsukatani, H.4
-
36
-
-
65449156892
-
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis
-
Pamuklar Z., Federico L., Liu S., et al. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J. Biol. Chem. 2009, 284:7385-7394.
-
(2009)
J. Biol. Chem.
, vol.284
, pp. 7385-7394
-
-
Pamuklar, Z.1
Federico, L.2
Liu, S.3
-
37
-
-
64849095442
-
Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo
-
Tomsig J.L., Snyder A.H., Berdyshev E.V., et al. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem. J. 2009, 419:611-618.
-
(2009)
Biochem. J.
, vol.419
, pp. 611-618
-
-
Tomsig, J.L.1
Snyder, A.H.2
Berdyshev, E.V.3
-
38
-
-
77952173274
-
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation
-
Albers H.M., Dong A., van Meeteren L.A., et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7257-7262.
-
(2010)
Proc. Natl. Acad. Sci. U. S. A.
, vol.107
, pp. 7257-7262
-
-
Albers, H.M.1
Dong, A.2
van Meeteren, L.A.3
-
39
-
-
82955187784
-
Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome
-
Dohi T., Miyauchi K., Ohkawa R., et al. Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. Clin. Chim. Acta 2012, 413:207-212.
-
(2012)
Clin. Chim. Acta
, vol.413
, pp. 207-212
-
-
Dohi, T.1
Miyauchi, K.2
Ohkawa, R.3
|